Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Intensified Chemotherapy in CRC After Resection of Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00208260
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : June 16, 2010
Chugai Pharmaceutical
Information provided by:
Institut du Cancer de Montpellier - Val d'Aurelle

Brief Summary:
Randomized, open label, multicentre phase II trial followed by phase III comparing overall survival after having selected the best experimental arm.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Liver Metastases Chemotherapy Drug: FOLFIRI Drug: FOLFOX-4 Drug: FOLFIRI-HD Drug: FOLFOX-7 Drug: FOLFIRINOX Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial Followed by Phase III Trial With Molecular Biology Study, Comparing a Standard Bi-therapy vs 3 Arms of Intensified Chemotherapy in Patients With Unresectable or Not Optimally Resectable Colorectal Cancer Liver Metastases.
Study Start Date : April 2004
Actual Study Completion Date : August 2007

Arm Intervention/treatment
Active Comparator: A
FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks

Active Comparator: B
Drug: FOLFOX-4
FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks

Experimental: C
High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks

Experimental: D
Drug: FOLFOX-7
FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks

Experimental: E
FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks

Primary Outcome Measures :
  1. Response [ Time Frame: end of chemotherapy ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: during study treatment ]
  2. Survival [ Time Frame: 2 years ]
  3. Secondary resection [ Time Frame: surgery after chemotherapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven adenocarcinoma of the colon or rectum without previous resection, or clinically asymptomatic (with or without stent)
  • Hepatic unresectable metastases R0: due to close vascular contact, or due to liver remaining mass less than 25 to 30 % of functional liver.
  • Not optimally resectable metastases
  • Extra-hepatic disease will be accepted in case of: asymptomatic primary tumour or tumor requiring no urgent surgery (in less than 3 months); three of less than three lung metastases (thoracic scan diameter less than 2 cm) and potentially respectable.
  • Synchronous and metachronous hepatic metastases
  • WHO performance status 0-1
  • Adjuvant chemotherapy allowed, except oxaliplatin and irinotecan based combination.
  • No prior treatment of the liver metastases, whatever.
  • Life expectancy equal or more than 3 months

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00208260

Layout table for location information
CRLC Val d'Aurelle
Montpellier, France, 34298
Sponsors and Collaborators
Institut du Cancer de Montpellier - Val d'Aurelle
Chugai Pharmaceutical
Layout table for investigator information
Principal Investigator: Marc YCHOU, MD, PhD CRLC Val d'Aurelle
Study Chair: Michel RIVOIRE, MD CRLC Leon Berard - Lyon

Layout table for additonal information Identifier: NCT00208260    
Other Study ID Numbers: METHEP/2004/22
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: June 16, 2010
Last Verified: June 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protective Agents
Vitamin B Complex